Cerebrovascular Agents in Gerontopsychopharmacotherapy

  • F. Hoffmeister
  • S. Kazda
  • F. Seuter
Part of the Handbook of Experimental Pharmacology book series (HEP, volume 55 / 2)

Abstract

Treatment of cerebral dysfunctions and disorders occurring mainly in the elderly by cerebral vasodilating agents seemed to gain its justification when Kety (1956) concluded that cerebral blood flow and oxygen consumption declines with age (Fig. 1). In an attempt to differentiate the extent to which decrease of cerebral blood flow is due to age or the effect of disease, Dastur et al. (1963) excluded effects of disease by selecting old persons in good health. Cerebral blood flow in these selected elderly persons did not differ from that of young ones. Since cerebral blood flow was low even in diseased elderly subjects with mild disorders, it was concluded that pathology is the main cause for decreased cerebral circulation in old age.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Achenbach, C., Klemme, E., Schueller, H., Ziskoven, R.: Tinofedrin and contraction. Eur. J. Physiol. 382, Suppl., R6 (1979)Google Scholar
  2. Acheson, E.J.: Platelet adhesiveness and cerebral vascular disease revisited. In: Platelet aggregation in the pathogenesis of cerebrovascular disorders (Abstracts: Round Table Conference, Rome — 1974), Fazio, C. (ed.), pp. 21–23Google Scholar
  3. Acheson, E.J., Danta, G., Hutchinson, E.C.: Controlled trial of dipyridamole in cerebral vascular disease. Br. Med. J. 1969 I, 614–615Google Scholar
  4. Affleck, D.C., Treptow, K.R., Herrick, H.D.: The effects of isoxsuprine hydrochloride (Vasodilan) on chronic cerebral arteriosclerosis. J. Nerv. Ment. Dis. 132, 335–338 (1961)PubMedGoogle Scholar
  5. Ali, M., McDonald, J.W.D.: Effects of sulfinpyrazone on platelet prostaglandin synthesis and platelet release of serotonin. J. Lab. Clin. Med. 89, 868–875 (1977)PubMedGoogle Scholar
  6. Aliprandi, G., Tantalo, V.: Physiopathologie des Innenohrs und Therapie der Perzeptionstaub-heit. Arzneim. Forsch. 29, 1287–1295 (1979)Google Scholar
  7. Allen, G.S., Banghart, S.B.: Cerebral arterial spasm: Part 9. In vitro effects of nifedipine on serotonin-, phenylephrine-, and potassium-induced contractions of canine basilar and femoral arteries. Neurosurgery 4, 37–42 (1979)PubMedGoogle Scholar
  8. Ally, A.I., Manku, M.S., Horrobin, D.F.: Dipyridamole: A possible potent inhibitor of thromboxane A2 synthetase in vascular smooth muscle. Prostaglandins 14, 607–609 (1977)PubMedGoogle Scholar
  9. Al-Mondhiry, H., Marcus, A.J., Spaet, T.H.: On the mechanism of platelet function inhibition by acetylsalicyclic acid. Proc. Soc. Exp. Biol. Med. 133, 632–636 (1970)PubMedGoogle Scholar
  10. Ambrozi, L., Neumayer, E.: Zerebrovaskuläre Insuffizienz und Hirnleistung. Wien. Klin. Wochenschr. 83, 188–192 (1971)PubMedGoogle Scholar
  11. Anderson, W.D., Kubicek, W.G.: Effects of betahistine HCl, nicotinic acid, and histamine on basilar blood flow in anaesthetized dogs. Stroke 2, 409–415 (1971)PubMedGoogle Scholar
  12. Anturane Reinfarction Trial Research Group: Sulfinpyrazone in the prevention of cardiac death after myocardial infarction. New Engl. J. Med. 298, 289–295 (1978)Google Scholar
  13. Arbus, L.: Circulation cérébrale et drogues. Médecine Practicienne 478, 147–152 (1972)Google Scholar
  14. Arfel, G., de Pommery, J., de Pommery, H., de Lavarde, M.: Modifications de l’électrogenèse cérébrale suscitées par la vincamine. Rev. Electroencephalogr. Neurophysiol. Clin. 4, 53–67 (1974)PubMedGoogle Scholar
  15. Arnaud, P., Kofman, J., Frederich, A., Faucon, G.: Sur les propriétés antifibrillantes des anesthésiques locaux. Compt. Rend. Soc. Biol. 159, No. 12, 2427–2430 (1965)Google Scholar
  16. Asano, T., Ochiai, Y., Hidaka, H.: Selective inhibition of separated forms of human platelet cyclic nucleotide phosphodiesterase by platelet aggregation inhibitors. Mol. Pharmacol. 13, 400–406 (1977)PubMedGoogle Scholar
  17. Aspirin Myocardial Infarction Study Research Group: A randomized, controlled trial of aspirin in persons recovered from myocardial infarction. J. Am. Med. Assoc. 243, 661–669 (1980)Google Scholar
  18. Aurousseau, M.: Pharmacologie comparée des alcaloides indolique et de leurs derivés agissant sur la circulation cérébral et le métabolisme du tissu nerveux. Chim. Thér. 6, 221–234 (1971)Google Scholar
  19. Aurousseau, M., Dupont, M., Rondeaux, G, Rondeaux, J.G: Variation de l’irrigation sanguine cérébrale sous l’influence de quelques dérivés indoliques apparentes à la vincamine. Chim. Thér. 7, 235–243 (1972)Google Scholar
  20. Bailey, J.M., Bryant, R.W., Feinmark, S.J., Makheja, A.N.: Differential separation of thromboxanes from prostaglandins by one and two-dimensional thin layer chromatography. Prostaglandins 13, 479–492 (1977)PubMedGoogle Scholar
  21. Ball, J.A.C., Taylor, A.R.: Effect of cyclandelate on mental functions and cerebral blood flow in elderly patients. Brit. Med. J. 1967 III, 525–528Google Scholar
  22. Bansal, B.C., Prakash, G, Arya, R.K., Gulati, S.K., Mittal, S.G: Serum lipids, platelets, and fibrinolytic activity in cerebrovascular disease. Stroke 9, 137–139 (1978)PubMedGoogle Scholar
  23. Barnett, H.J.M.: Pathogenesis of transient ischemic attacks. In: Cerebrovascular diseases. Scheinberg, P. (ed.), pp. 1–21. New York: Raven Press 1976Google Scholar
  24. Barnett, H.J.M.: Aspirin and sulfinpyrazone in threatened stroke — the results of the cancidian collaborative double-blind trial. In: Acetylsalicyclic acid in cerebral ischemia and coronary heart disease. Breddin, K., Dorndorf, W., Loew, D., Marx, R. (eds.), p.93. Stuttgart, New York: Schattauer 1978Google Scholar
  25. Barnett, H.J.M.: The pathophysiology of transient cerebral ischemic attacks. Therapy with platelet antiaggregants. Med. Clin. North Am. 63, 649–679 (1979)PubMedGoogle Scholar
  26. Barnett, H.J.M., and the Canadian Cooperative Study Group: A randomized trial of aspirin and sulfinpyrazone in threatened stroke. New Engl. J. Med. 299, 53–59 (1978)Google Scholar
  27. Barnett, H.J.M., McDonald, B.W.D., Sackett, D.L.: Aspirin-effective in males threatened with stroke. Stroke 9, 295–298 (1978)PubMedGoogle Scholar
  28. Baron, G.D., Kreye, V.A.W.: Effects of drugs on 45Ca uptake by isolated vascular smooth muscle membranes. Eur. J. Physiol. 343, Suppl. R54 (1973)Google Scholar
  29. Bartels, H., Schneider, B.: Kontrolle der pharmakodynamischen Wirkung von Fludilat bei der Behandlung der cerebrovasculären Insuffizienz. Med. Welt 29, 1056–1060 (1978)PubMedGoogle Scholar
  30. Baumgartner, H.R.: Wirkungsmechanismen von Plättcheninhibitoren. Ther. Umsch. 34, 341–346 (1977)PubMedGoogle Scholar
  31. Baumgartner, H.R., Muggli, R.: Effect of acetylsalicyclic acid on platelet adhesion to sub-endothelium and the formation of mural thrombi. Thromb. Diath. Haemorrh. Suppl. 60, 345(1974)Google Scholar
  32. Beckmann, G., Herrmann, E.: Untersuchungen zur Beeinflußbarkeit der Innenohrdurchblutung. Arch. Klin. Exp. Ohren-Nasen-Kehlkopfheilkd. (Kongreßbericht IL Teil) 194, 534–538 (1970)Google Scholar
  33. Beghi, E.: Naftidrofuryl in drug treatment and devention in cerebrovascular disorders. In: Tognoni, G., Garattini, S. (eds.), pp. 211–222. Amsterdam: Elsevier North Holland Biomedical Press 1979Google Scholar
  34. Behrens, E.: Medikamentöse Beeinflussung der Hirndurchblutung durch Stutgeron. Med. Welt 38, 2029–2031 (1966)PubMedGoogle Scholar
  35. Benzi, G.: Drugs action on cerebral energy state during and after various hypoxic conditions. Arch. Int. Pharmacodyn. 236, 234–251 (1978)PubMedGoogle Scholar
  36. Benzi, G.: Effects of chronic treatment with some drugs on the enzymatic activities of the rat brain. Biochem. Pharmacol. 28, 2703–2708 (1979)PubMedGoogle Scholar
  37. Bernard, A., Goffart, J.M.: A double-blind cross-over clinical evaluation of cinnarizine. Clin. Trials J. 5, 945–947 (1968)Google Scholar
  38. Bernardi, L.: Von den Mutterkorn-Alkaloiden zum Nicergolin/Chemische Gesichtspunkte. Arzneim. Forsch. 29, 1204–1206 (1979)Google Scholar
  39. Best, L.C., Martin, T.J., McGuire, M.B., Preston, F.E., Russell, R.G.G., Segal, D.S.: Dipyridamole and platelet function. Lancet 1978 II, 846Google Scholar
  40. Best, L.C., McGuire, M.B., Jones, P.B.B., Holland, T.K., Martin, T.J., Preston, F.E., Segal, D.S., Russell, R.G.B.: Mode of action of dipyridamole of human platelets. Thromb. Res. 16, 367–379 (1979)PubMedGoogle Scholar
  41. Betz, E.: Pharmakologie des Gehirnkreislaufs. In: Der Hirnkreislauf. Gänshirt, H. (ed.), pp. 412–440. Stuttgart: Thieme 1972Google Scholar
  42. Birkmayer, W., Seemann, D., Zita, G.: Objektivierung des zerebralen Nutritionseffektes. Szin-tigraphische Untersuchungen. Münch. Med. Wochenschr. 107, 2410–2413 (1965)PubMedGoogle Scholar
  43. Biro, K., Karpati, E., Szporny, L.: Protective activity of ethyl apovincaminate on ischaemic anoxia of the brain. Arzneim. Forsch. 26, 1918–1920 (1976)Google Scholar
  44. Boden, U., Boden, C., Ruehland, W.: Zur klinischen Wirksamkeit von Zinnarizin bei geriatri-schen Patienten. Doppelter Blindversuch. Zentralbl. Pharm. Pharmakother. Laborato-riumsdiagn. 111, 1257–1266 (1973)Google Scholar
  45. Böhlau, V.: Beitrag zur medikamentösen Therapie in der Rehabilitation vorzeitiger Altersbeschwerden. Med. Welt 26, 233–235 (1975)PubMedGoogle Scholar
  46. Bolton, T.B.: Mechanisms of action of transmitter and other substances on smooth muscle. Physiol. Rev. 59, 606–718 (1979)PubMedGoogle Scholar
  47. Borgioli, M., Merendino, E., Ricci, B.: Therapeutische Wirksamkeit von Nicergolin in der Oph-thalmologie/Fluoreszenzretinolographischer Beitrag. Arzneim. Forsch. 29, 1311–1316 (1979)Google Scholar
  48. Born, G.V.R.: Haemodynamic and biochemical interactions in intravascular platelet aggregation. In: Blood cells and vessel wails functional interactions, pp. 61–77. Amsterdam, Oxford, New York: Excerpta Medica 1980Google Scholar
  49. Born, G.V.R., Mills, D.C.: Potentiation of the inhibitory effect of adenosine on platelet aggregation by drugs that prevent its uptake. J. Physiol. (Lond.) 202, 41 (1969)Google Scholar
  50. Botez, M.: Betahistidine hydrochloride in the treatment of vertebro-basilar insufficiency. Encephale 1, 279–286 (1975)PubMedGoogle Scholar
  51. Brailowski, S., Walter, S., Vuillon-Cacciutolo, G., Serbanescu, T.: Alcaloïdes indoliques induisant on non un tremblement: Effets sur l’épilepsie photosensible du papio papio. C.R. Soc. Biol. 1969, 1190–1193(1975)Google Scholar
  52. Bravermann, A.M., Naylor, R.: Vasoactive substances in the management of elderly patients suffering from dementia. Mod. Geriatrics 5, 20–29 (1975)Google Scholar
  53. Breddin, K.: Die Thrombozytenfunktion bei hämorrhagischen Diathesen, Thrombosen und Gefäßkrankheiten. Stuttgart: Schattauer 1968Google Scholar
  54. Breddin, K., Grun, H., Krzywanek, H.J., Schremmer, W.P.: On the measurement of spontaneous platelet aggregation. The platelet aggregation test III. Methods and first clinical results. Thromb. Haemostas. 35, 669–691 (1976)Google Scholar
  55. Brenner, G.: Vergleichende Untersuchungen über die Beeinflussung der O2-Aufnahme von Leber- und Hirnhomogenaten der Ratte durch Xantinol-nicotinat und Nikotinsäure. Arzneim. Forsch. 24, 321–325 (1974)Google Scholar
  56. Brenner, G., Brenner, H.: Die Einwirkung von Xantinol-nicotinat auf den Stoffwechsel des Gehirns. Tierexperimentelle Untersuchungen über die Beeinflussung der Glukose-14C-Per-meation und der Pyridin- und Adenin-nucleotide. Arzneim. Forsch. 22, 754–759 (1972)Google Scholar
  57. Brückner, G.W., Jansen, W.: Zur Therapie der zerebrovaskulären Insuffizienz. Eine psychometrische Doppelblindstudie mit Xantinol-Nicotinat. Münch. Med. Wochenschr. 121, 861–864 (1979)Google Scholar
  58. Bunag, R.D., Douglas, C.R., Imai, S., Berne, R.M.: In vitro inhibition of adenosine deaminase by persantin. Fed. Proc. 22, 642 (1963)Google Scholar
  59. Busse, W.-D., Seuter, F.: Influence on thromboxane and malondialdehyde synthesis in human thrombocytes by various inhibitors of platelet function. In: Arachidonic acid metabolism in inflammation and thrombosis. Brune, K., Baggiolini, F. (eds.), pp. 127–137. Stuttgart: Birkhäuser 1979Google Scholar
  60. Candelise, L.: Suloctidil and bencyclane in drug treatment and prevention in cerebrovascular disorders. In: Tognoni, G., Garattini, S. (eds.), pp. 205–210. Amsterdam: Elsevier North Holland Biomedical Press 1979Google Scholar
  61. Capote, B., Parikh, N.: Cyclandelate in the treatment of senility: A controlled study. J. Am. Geriatr. Soc. 26, 360–362 (1978)PubMedGoogle Scholar
  62. Cazenave, J.P., Kinlough-Rathbone, L., Packham, M.A., Mustard, J.F.: The effect of acetyl-salicyclic acid and indomethacin on rabbit platelet adherence to collagen and the sub-endothelium in the presence of a low or high hematocrit. Thromb. Res. 13, 971–981 (1978)PubMedGoogle Scholar
  63. Clerck, F. de, Vermylen, J., Reneman, R.: Effects of suprofen, an inhibitor of prostaglandin biosynthesis, on platelet function, plasma coagulation and fibrinolysis. I. In vitro experiments. Arch. Int. Pharmacodyn. 216, 263–279 (1975)PubMedGoogle Scholar
  64. Cooper, D.R., Lewis, G.P., Lieberman, G.E., Webb, H., Westwick, J.: ADP metabolism in vascular tissue, a possible thrombo-regulatory mechanism. Thromb. Res. 14, 901–914 (1979)PubMedGoogle Scholar
  65. Cosnier, M., Cheucle, M., Rispat, G., Streichenberger, G.: Influence of hypercapnia on the cerebrovascular activities of some drugs used in the treatment of cerebral ischemia. Arzneim. Forsch. 27, 1566–1569 (1977)Google Scholar
  66. Craigen, L., Harper, A.M., Kazda, S.: Effect of a calcium antagonist (nimodipine) on CBF and metabolism. (in press) (1981)Google Scholar
  67. Csaba, B., Toth, S., Molnar, G.: Benzcyclan, a new anti-serotonin drug. A pharmacological study on the effect of benzcyclan in relationship to its anti-serotonin properties. Arzneim. Forsch. 19, 1726–1728 (1969)Google Scholar
  68. Cucuianu, M.P., Nishizawa, E.E., Mustard, J.F.: Effect of pyrimidopyrimidine compounds on platelet function. J. Lab. Clin. Med. 77, 958–974 (1971)PubMedGoogle Scholar
  69. Danielczyk, W.: Neue therapeutische Aspekte bei der Rehabilitation zerebraler Gefäßkranker. Therapiewoche 21, 307–312 (1971)Google Scholar
  70. Dastur, D.K., Laen, M.H., Hansen, D.B., Kety, S.S., Butler, R.N., Perlin, S., Sokoloff, L.: Effects of ageing on cerebral circulation and metabolism in man. In: Human ageing: A biological and behavioral study. PHS Publication Nr.986, pp. 57–76. Washington D.C.: US Government Printing Office 1963Google Scholar
  71. David, G., Kenedi, I.: The antiserotonin effect of benzcyclan. Acta Physiol. Hung. 33, Suppl. 2, 75 (1967)Google Scholar
  72. Davies, G., Hamilton, S., Hendrickson, E., Levy, R., Post, F.: The effect of cyclandelate in depressed and demented patients: A controlled study in psychogeriatric patients. Age Ageing 6, 156–162 (1977)PubMedGoogle Scholar
  73. Davies, J.A., Menys, V.C.: Effect on sulphinpyrazone (SP) aspirin (ASA), and dipyridamole (DP) on platelet-vessel wall interaction after oral administration to rabbits. Thromb. Haemostas. 42, 197 (1979)Google Scholar
  74. De Cree, J., De Cock, W., Geukens, H., De Clerck, F., Beerens, M., Verhaegen, H.: The Theological effects of cinnarizine and flunarizine in normal and pathologic conditions. Angiology 30, 505–515(1979)PubMedGoogle Scholar
  75. Dhrymiotis, A.D., Whittier, J.R.: Die Wirkung eines Vasodilatans, Isoxsuprin, auf Zustände von cerebraler Ischämie. Curr. Therap. Res. 4, 1–7 (1962)Google Scholar
  76. Didisheim, P.T.: Inhibition by dipyridamole of arterial thrombosis in rats. Thromb. Diath. Haemorrh. 20, 257–266 (1968)PubMedGoogle Scholar
  77. Didisheim, P.T., Fuster, V.: Actions and clinical status of platelet-suppressive agents. Semin. Hematol. 15, 55–72 (1978)PubMedGoogle Scholar
  78. Didisheim, P.T., Owen, C.A.: Effect of dipyridamole (PersantinR) and its derivatives on thrombosis and platelet function. Thromb. Diath. Haemorrh. Suppl. 42, 267–275 (1970)Google Scholar
  79. Di Minno, G., De Gaetano, G., Silver, M.J.: Dipyridamole (D) reduces the effectiveness of prostaglandin (PG)I2, PGD2, and PGE1 as inhibitors of platelet aggregation in human platelet-rich plasma (PRP). Thrombos. Haemostas. 42, 198 (1979)Google Scholar
  80. Di Minno, G., Silver, M.J., de Gaetano, G.: Ingestion of dipyridamole reduces inhibitory effect of prostacyclin on human platelets. Lancet 1979 II, 701–702Google Scholar
  81. Dinkhoff, U.: Fludilat-Therapie bei zerebraler Mangeldurchblutung. Med. Welt 26, 522–524 (1975)PubMedGoogle Scholar
  82. Di Perri, T., Forconi, S., Guerrini, M., Loghi Pasini, F., Del Cipolla, R., Rossi, C., Agnusdei, D.: Action of cinnarizine on the hyperviscosity of blood in patients with peripheral obliterative arterial disease. Proc. R. Soc. Med. 70, Suppl. 8, 25–28 (1977)PubMedGoogle Scholar
  83. Duguid, J.B.: Pathogenesis of atherosclerosis. Lancet 1949 II, 925Google Scholar
  84. Dunlop, E.: Chronic cerebrovascular insufficiency treated with papaverine. J. Am. Geriat. Soc. 16, 343–349 (1968)Google Scholar
  85. Dupont, M., Aurousseau, M.: Variations de la circulation cérébrale sous l’influence de quelques dérivés indoliques apparentes à la vincamine. Chim. ther. 5, 366 (1970)Google Scholar
  86. Dyken, M.L.: Clinical studies of cerebral ischaemia and antiplatelet drugs. In: Acetylsalicyclic acid in cerebral ischaemia and coronary heart disease. Breddin, K., Dorndorf, F.W., Loew, D., Marx, R. (eds.), pp. 79–84. Stuttgart, New York: F.K. Schattauer 1978Google Scholar
  87. Edvinsson, L., Owman, C.H.: Pharmacological identification of adrenergic α- and ß, cholingeric (muscarine and nicotinic), histaminergic H1 and H2, and serotonergic receptors in isolated histaminergic H1 and H2, and serotonergic receptors in isolated intra- and extracranial vessels. In: Blood flow and metabolism in the brain. Harper, A.M., Jennett, W.B., Miller, J.D., Rowan, J.O. (eds.), pp. 118–125. Edinbourgh, London: Churchill Livingstone 1975Google Scholar
  88. Eichhorn, O.: Zur Behandlung der ischämischen Hirnschädigung. Med. Welt 42, 2314–2318 (1969)PubMedGoogle Scholar
  89. Ekström-Jodal, B., von Essen, C., Haggendal, E., Roos, B.E.: Effects of noradrenaline, 5-hy-droxytryptamine, and dopamine on the cerebral blood flow in the dog. Stroke 4, 367–368 (1973)Google Scholar
  90. Elliott, C.G., Brown, A.L., Smith, T.C.G.: Multi-centre general practitioner trial of isoxsuprine in cerebrovascular disease: a pilot study. Curr. Med. Res. Opinion 1, 554–562 (1973)Google Scholar
  91. Emmons, P.R., Harrison, M.J.G., Honour, A.J., Mitchell, J.R.A.: Effect of dipyridamole on human platelet behavior. Lancet 1965 II, 603–606Google Scholar
  92. Enz, A., Iwangoff, P., Markstein, R., Wagner, H.: The effect of hydergine on the enzymes involved in cAMP turnover in the brain. Triangle 14, 90–92 (1975)PubMedGoogle Scholar
  93. Espagno, S., Lazorthes, Y., Arbus, L.: Techniques d’étude hémodynamique et métabolique d’un médicament à visée vasculaire cérébrale. Thérapeutique 45, 888–890 (1969)PubMedGoogle Scholar
  94. Fazekas, J., Bessman, A., Cotsonas, N., Jr., Alman, R.: Cerebral hemodynamics in cerebral arteriosclerosis. J. Gerontol. 8, 137–145 (1953)PubMedGoogle Scholar
  95. Feine-Haake, G.: Zur Objektivierung der therapeutischen Wirksamkeit von Trental 400. Fortschr. Med. 95, 48–58 (1977)PubMedGoogle Scholar
  96. Fields, W.S.: Transient cerebral ischemic attackes (TIA’s). In: Brain and heart infarct. Zülch, K.J., Kaufmann, W., Hossmann, K.-A., Hossmann, V. (eds.), pp. 281–283. Berlin, Heidelberg, New York: Springer 1977Google Scholar
  97. Fields, W.S., Lemak, N.A.: Controlled trial of aspirin in cerebral ischemia; study design, surveillance, and results. In: Acetylsalicyclic acid in cerebral ischemia and coronary heart disease. Breddin, K., Dorndorf, W., Loew, D., Marx, R. (eds.), pp. 85–91. Stuttgart, New York: Schattauer 1978Google Scholar
  98. Fields, W.S., Lemak, N.A., Frankowski, R.F., Hardy, R.J.: Controlled trial of aspirin in cerebral ischemia, Part I. Stroke 8, 301–316 (1977)PubMedGoogle Scholar
  99. Fields, W.S., Lemak, N.A., Frankowski, R.F., Hardy, R.J.: Controlled trial of aspirin in cerebral ischemia, Part II: Surgical group. Stroke 9, 309–319 (1978)PubMedGoogle Scholar
  100. Fieschi, C., Volante, F., Battistini, N., Passero, S.: Experimental cerebral ischemia by arachi-donic acid-induced platelet emboli. In: Brain and heart infarct. Zülch, K.J., Kaufmann, W., Hossmann, K.-A., Hossmann, V. (eds.), pp. 261–270. Berlin, Heidelberg, New York: Springer 1977Google Scholar
  101. Fieschi, C., Battistini, N., Nardini, M., D’Ettore, M., Volante, F., Zanette, E.: Clinical management of cerebrovascular disease. In: Atherosclerosis reviews. Paoletti, R., Gotto, A.M., jr. (eds.), vol.2, pp. 155–174. New York: Raven Press 1977Google Scholar
  102. Fieschi, C., Battistini, N., Volante, F., Passero, S.: Protective effects of drugs against embolic TIA in an animal model. In: Acetylsalicyclic acid in cerebral ischemia and coronary heart disease. Breddin, K., Dorndorf, W., Loew, D., Marx, R. (eds.), pp. 119–125. Stuttgart, New York: Schattauer 1978Google Scholar
  103. Fine, E.W., Lewis, D., Villa Landa, I., Blakemore, C.B.: The effect of cyclandelate on mental function in patients with arteriosclerotic brain disease. Brit. J. Psychiat. 117, 157–161 (1970)PubMedGoogle Scholar
  104. Fleckenstein, A., Fleckenstein-Grün, G.: Zur kombinierten Anwendung von Herzglykosiden und Ca-Antagonisten. Arzneim. Forsch. 27, 736–742 (1977)Google Scholar
  105. Fontaine, L., Grand, M., Szarvasi, E.: Premières comparaisons, in vitro et in vivo, des activités antispasmodiques dans une série de dialcoylaminoesters et éthéroxydes. Compt. Rend. 262, 719–721 (1966)Google Scholar
  106. Fontaine, L., Grand, M., Chabert, J., Szarvasi, E., Bayssat, M.: Pharmacologie générale d’une substance nouvelle vasodilatrice, le naftidrofuryl. Bull. Chim. Thér. 6, 463–469 (1968)Google Scholar
  107. Fontaine, L., Grand, M., Szarvasi, E., Bayssat, M.: Etude de l’activité vasodilatrice du naftidrofuryl. Bull. Chim. Thér. 1, 39–43 (1969)Google Scholar
  108. Fossey, F., Pasquier, Ch.: Utilisation, dans les encéphalopathies chroniques, d’un médicament oxygénateur cérébral. Rev. Neuropsychiatr. Infant. 20, 887–891 (1972)PubMedGoogle Scholar
  109. Fournier, A.M., Mourou, M.: Naftidrofuryl et spasmes carotidiens. J. Radiol. Electrol. Med. Nucl. 53, 897–901(1972)PubMedGoogle Scholar
  110. Gänshirt, H.: Zerebrale Durchblutungsstörungen. Therapiewoche 28, 835–839 (1978)Google Scholar
  111. Gärtner, E., Enzengross, H.G., Vlahov, V., Schanzenbächer, P., Brandt, H., Betz, E.: Durchblutung, Sauerstoffdruck und pH des zerebralen Kortex unter Einwirkung von Fludilat. Arzneim. Forsch. 25, 887–891 (1975)Google Scholar
  112. Gaetano, G. de, Miragliotta, G., Roncucci, R., Lansen, J., Lambelin, G.: Suloctidil: A novel inhibitor of platelet aggregation in human beings. (1). Thromb. Res. 8, 361–371 (1976)PubMedGoogle Scholar
  113. Gallus, A.S., Hirsh, J.: Antithrombotic drugs. Drugs 12, 21–68, 132–157 (1976)Google Scholar
  114. Garcia Guerra, C.M.: Evaluacion clinica del fludilat en la insuficienca vascular cerebral. Prensa Med. Mex. 42, 504–508 (1978)Google Scholar
  115. Gautier, J.C.: Arterial pathology in cerebral ischaemia and infarction. In: Progress in stroke. Greenhalgh, R.M., Rose, F.C. (eds.), pp. 28–39. Kent: Pitman Medical 1979Google Scholar
  116. Genton, E., Barnett, H.J.M., Fields, W.S., Gent, M., Hoak, J.C.: Cerebral ischemia: The role of thrombosis and of antithrombotic therapie. Stroke 8, 150–175 (1977)PubMedGoogle Scholar
  117. Glatt, A., Klebs, K., Koella, W.P.: Influence of vincamine and piracetam on sleep-waking pattern of the cat. Biol. Psychiatry 13, 417–427 (1979)Google Scholar
  118. Gloning, K., Klausenberger, E.M.: Untersuchungen über die Hirngefäßfunktion im Bewegungsfilm. Wien. Klin. Wochenschr. 70, 145–149 (1958)PubMedGoogle Scholar
  119. Godfraind, T.: Actions of suloctidil and of the Ca-antagonist cinnarizine on the rat aorta. Arch. Int. Pharmacodyn. 221, 342–343 (1976)PubMedGoogle Scholar
  120. Godfraind, T., Kaba, A.: Blockade or reversal of the contraction induced by calcium and adrenaline in depolarized arterial smooth muscle. Br. J. Pharmacol. 36, 549–560 (1969)PubMedGoogle Scholar
  121. Godfraind, T., Sturbois, X.: Les lésions du myocarde provoquées par L’Isoprénaline et leur prevention par la cinnarizine. Arch. Int. Pharmacodyn. 199, 203–205 (1972)PubMedGoogle Scholar
  122. Gossetti, B., Ventura, M., Damiano, M., Bait, C., Zaccaria, A.: CBF changes after (-) eburnamonine infusion in patients with cerebrovascular insufficiency. Eur. Neurol. 17, 171–172 (1979)Google Scholar
  123. Gotshall, R.K., Harker, L.A.: Using antithrombotic therapy in ischemic cerebrovascular disease. Geriatrics 32, 101–104 (1977)PubMedGoogle Scholar
  124. Gottstein, U.: Der Hirnkreislauf unter dem Einfluß vasoaktiver Substanzen. Einzeldarstellungen aus der theoretischen und klinischen Medizin, Bd. 15. Heidelberg: A. Hüthig 1962Google Scholar
  125. Gottstein, U.: Pharmacological studies of total cerebral blood flow in man with comments on the possibility of improving regional cerebral blood flow of drugs. Acta Neurol. Scand. Suppl. 14, 136–141 (1965)Google Scholar
  126. Gottstein, U.: The effect of drugs on cerebral blood flow especially in patients of older age. Pharmakopsychiatr. Neuro-Psychopharmakol. 2, 100–109 (1969)Google Scholar
  127. Grasser, K., Petocz, L., Komlos, E.: Effect of basic ethers of cycloalkanol derivatives on gastric juice secretion and experimental ulcer in the rat. Acta Physiol. Hung. 30, 369 (1966)Google Scholar
  128. Griguer, P., Brochier, M., Raynaud, R.: Étude de l’effet inhibiteur du dipyridamole sur l’adhe-sivite et l’agrégation plaquettaires „in vitro“et „in vivo“. Ann. Cardiol. Angeiol. 24, 2–36 (1975)Google Scholar
  129. Gryglewski, R.J., Bunting, S., Moncada, S., Flower, R.J., Vane, J.P.: Arterial walls are protected against deposition of platelet thrombi by a substance (prostaglandin X) which they make from prostaglandin endoperoxides. Prostaglandins 12, 685–713 (1976)PubMedGoogle Scholar
  130. Gurewich, W., Lipinski, B.: Evaluation of antithrombotic properties of suloctidil in comparison with aspirin and dipyridamole. Thromb. Res. 9, 101–108 (1976)PubMedGoogle Scholar
  131. Guyer, B.M.: The management of cerebrovascular disease with isoxsuprine resinate (Defen-cin CP). Clin. Trials. J. 14, 159–163 (1977)Google Scholar
  132. Guyer, B.M.: Cerebrovascular disease in the elderly: Response to isoxsuprine resinate (Defen-cin CP) therapy. Clin. Trials J. 15, 49–53 (1978)Google Scholar
  133. Gygax, P., Wiernsperger, N., Meier-Ruge, W., Baumann, T.: Effect of papaverine and dihydroergotoxine mesylate on cerebral microflow EEG, and pO2 in oligemic hypotension. Gerontology 24, 14–22 (1978)PubMedGoogle Scholar
  134. Hall, P.: Cyclandelate in the treatment of cerebral arteriosclerosis. J. Am. Geriatr. Soc. 24, 41–45 (1976)PubMedGoogle Scholar
  135. Hamberg, M., Svensson, J., Samuelsson, B.: Mechanism of antiaggregating effect of aspirin on human platelets. Lancet 1974, II, 223–224Google Scholar
  136. Hamberg, M., Svensson, J., Samuelsson, B.: Thromboxanes: A new group of biologically active compounds derived from prostaglandin endoperoxides. Proc. Natl. Acad. Sci. U.S.A. 72, 2994–2998 (1975)PubMedGoogle Scholar
  137. Handa, J.: Cerebral vascular effects of a new derivative of 1,4-dihydropyridine (YC-93), with special reference to its effect on the experimental basilar artery spasm in cats. Arch. Jpn. Chir. 44, 343–351 (1976)Google Scholar
  138. Handa, J., Yoneda, S., Koyama, T., Matsuda, M., Handa, H.: Experimental cerebral vasospasm in cats: Modification by a new synthetic vasodilator YC-93. Surg. Neurol. 3, 195–199 (1975)PubMedGoogle Scholar
  139. Handa, J., Koyama, T., Tsuji, H., Ishijima, Y., Teraura, T.: Clinical effect of a new 1,4-dihydropyridine derivative, YC-93, in patients with cerebrovascular diseases. Arch. Jap. Chir. 48, 400–403 (1979)Google Scholar
  140. Harker, I.A., Slichter, S.J.: Studies of platelet and fibrinogen kinetics in patients with prosthetic heart valves. New Engl. J. Med. 283, 1302–1305 (1970)PubMedGoogle Scholar
  141. Harker, I.A., Slichter, S.J.: Arterial and venous thromboembolism: Kinetic characterization and evaluation of therapy. Thromb. Diath. Haemorrh. 31, 188–203 (1974)PubMedGoogle Scholar
  142. Harrison, M.J.G.: Evidence for thromboembolism as a cause of transient cerebral ischemia. In: Acetylsalicylic acid in cerebral ischemia and coronary heart disease. Breddin, K., Dorndorf, F.W., Loew, D., Marx, R. (eds.), pp. 75–77. Stuttgart, New York: F.K. Schattauer 1978Google Scholar
  143. Harrison, M.J.G., Marshall, J., Meadows, J.C., Ross Russel, R.W.: Effect of aspirin in amaurosis fugax. Lancet 1971. II, 743Google Scholar
  144. Harwart, D.: The treatment of chronic cerebrovascular insufficiency: A double-blind study with pentoxifylline (“Trental” 400). Curr. Med. Res. Opin. 6, 73–84 (1979)PubMedGoogle Scholar
  145. Hass, W.K.: Aspirin for the lumping brain. Stroke 8, 299–301 (1977)PubMedGoogle Scholar
  146. Haupt, R., Isermann, H.: Zur Lern- und Konzentrationsfähigkeit von Patienten in höherem Lebensalter mit depressivem Syndrom bei cerebralen Durchblutungsstörungen. Nervenarzt 47, 269–271 (1976)PubMedGoogle Scholar
  147. Heinsius, E., Flamm, P.: Ophthalmologische Erfahrungen mit dem neuen Xanthin-Körper BL 191. Med. Klin. 68, 1540–1542 (1973)PubMedGoogle Scholar
  148. Heiss, W.D.: Drug effect on regional cerebral blood flow in focal cerebrovascular disease. J. Neurol. Sci. 19, 461–482 (1973)PubMedGoogle Scholar
  149. Heiss, W.D., Zeiler, K.: Medikamentöse Beeinflussung der Hirndurchblutung. Pharmakotherapie 1, 137–144 (1978)Google Scholar
  150. Heiss, W.D., Prosenz, P., Gloning, K., Tschabitscher, H.: Regional and total cerebral blood flow under vasodilating drugs. In: Brain and blood flow. Ross Russell, R.W. (ed.), pp. 270–276. London: Pitman 1970Google Scholar
  151. Held, K.: Experimentelle Untersuchungen über Wirkung und Wirkungsmechanismus von Xan-tinol-nicotinat beim Menschen im Sauerstoffmangel. Therapiewoche 23, 3270–3272 (1973)Google Scholar
  152. Held, K., Wünsche, O., Reuter, N.: Die Wirkung von Xantinol-Nicotinat auf den Menschen im Sauerstoffmangel der Höhe. Ärztl. Prax. 25, 91–93 (1973)Google Scholar
  153. Henry, P.D., Borda, L., Schuchlieb, R.: Chronotropic and inotropic effects of vasodilators. In: International Adalat® Pannell discussion. Lichtlen, P.R., Kimura, E., Taira, N. (eds.), pp. 14–23. Amsterdam: Excerpta Medica 1979Google Scholar
  154. Herrschaft, H.: Kann die Hirndurchblutung medikamentös verbessert werden? Schweiz. med. Wochenschr. 107, 581–583 (1977)PubMedGoogle Scholar
  155. Herrschaft, H.: Möglichkeiten der medikamentösen Behandlung der zerebralen Mangeldurchblutung. Therapiewoche 27, 4525–4534 (1979)Google Scholar
  156. Herrschaft, H., Gleim, F., Schmidt, H., Duss, P.: Das Verhalten der regionalen Hirndurchblutung unter dem Einfluß von Bencyclan. Quantitative örtliche Hirndurchblutungsmessungen bei Gesunden und Kranken mit zerebrovaskulärer Insuffizienz im Wachzustand und leichter Allgemeinnarkose. Med. Klin. 70, 896–903 (1975)PubMedGoogle Scholar
  157. Herzfeld, U., Wittgen, M.: Veränderung der zerebralen Zirkulationszeit unter dem Einfluß von Hydergin. Ärztl. Forsch. 25, 224–230 (1971)PubMedGoogle Scholar
  158. Herzfeld, U., Christian, W., Oswald, W.D., Ronge, J., Wittgen, M.: Zur Wirkungsanalyse von Hydergin im Langzeitversuch. Med. Klin. 67, 1118–1125 (1972)PubMedGoogle Scholar
  159. Heyck, H.: Der Einfluß der Nikotinsäure auf die Hirndurchblutung und den Hirnstoffwechsel bei Cerebralsklerosen und anderen diffusen Durchblutungsstörungen des Gehirns. Schweiz. Med. Wschr. 92, 226–231 (1962)PubMedGoogle Scholar
  160. Hockwin, O., Korte, I., Loth, C., Ohrloff, Ch., Fuss, R., Schmidt, G.: Action of bencyclane-hydrogen-fumarate on the carbohydrate metabolism of bovine lens homogenates. Arzneim. Forsch. 27, 1417–1420 (1977)Google Scholar
  161. Hoeft, HJ.: Fludilat im Doppelblindversuch zur Behandlung zerebraler und peripherer Durchblutungsstörungen. Therapiewoche 22, 905–911 (1972)Google Scholar
  162. Hoffmeister, F.: Cerebrovascular diseases: Drugs and methods. Proceedings of the International Symposium “Experimental and clinical methodologies for study of acute and chronic cerebrovascular diseases, pp. 243–247. Oxford, New York: SIR Pergamon Press 1981Google Scholar
  163. Hoffmeister, F., Kazda, S., Krause, H.P.: Influence of nimodipine (BAY e 9736) on the pos-tischaemic changes of brain function. Acta Neurol. Scand. 60, 358–359 (1979)Google Scholar
  164. Horch, U., Kadatz, R., Kopitar, Z., Ritsehard, J., Weisenberger, H.: Pharmacology of dipyridamole and its derivatives. Thromb. Diath. Haemorrh. Suppl. 42, 253–266 (1970)Google Scholar
  165. Horrobin, D.F., Ally, A.I., Manku, M.S.: Dipyridamole and platelet aggregation. Lancet 1978 II, 270Google Scholar
  166. Horton, G.E., Johnson, P.C.: The application of radioisotopes to the study of cerebral blood flow, comparison of three methods. Angiology 15, 70–74 (1964)PubMedGoogle Scholar
  167. Hossmann, V.: Coagulation disturbanas in cerebroviscular disorders. In: Brain and heart infarct. Zülch, K.J., Kaufmann, W., Hossmann, K.-A., Hossmann, V. (ed.), pp. 81–92. Berlin, Heidelberg, New York: Springer 1977Google Scholar
  168. Hünermann, B., Felix, R., Wesener, K., Winkler, C.: Zur Wirkung von Papaverinhydrochlorid auf die Hirnzirkulation. Arzneim. Forsch. 25, 652–653 (1975)Google Scholar
  169. Hussain, S.M.A., Gedye, J.L., Naylor, R., Brown, A.L.: The objective measurement of mental performance in cerebrovascular disease. Practicioner 216, 222–228 (1976)Google Scholar
  170. Hyams, D.E.: Cerebral function and drug therapy: The use of cerebral vasodilators “vasorelax-ans”, “haemokinators”, and “activators”. In: Textbook of geriatric medicine and gerontology, IInd Edition, J.C. Brocklehurst (ed.), pp. 671–711. Edinbourgh: Churchill Livingstone 1978Google Scholar
  171. Iliff, L.D., Du Boulay, G.H., Marshall, I., Ross Russel, R.W., Symon, L.: Wirkung von Nicergolin auf die Gehirndurchblutung. Arzneim. Forsch. 29, 1277–1279 (1979)Google Scholar
  172. Imparato, A.M., Riles, T.S., Gorstein, F.: The carotid bifurcation plaque: pathologic findings associated with cerebral ischemia. Stroke 10, 238–245 (1979)PubMedGoogle Scholar
  173. Irvine, R.E., Greenfield, P.R., Griffith, D.G.C., Paget, S.C., Strouthidis, T.M., Vaughan, V.St.G.: Cinnarizine in cerebrovascular disease. Geront. Clin. 12, 297–301 (1970)PubMedGoogle Scholar
  174. Iwanami, M., Shieanuma, T., Fujimoto, M., Kawai, R., Murakami, M.: Synthesis of new water-soluble dihydropyridine vasodilators. Chem. Pharm. Bull. 27, 1426–1440 (1979)PubMedGoogle Scholar
  175. Jäger, W., Scharrer, I., Satkowski, U., Breddin, K.: Thrombozyten-aggregationshemmende Wirkung von Bencyclan in vitro und in vivo. Arzneim. Forsch. 25, 1938–1944 (1975)Google Scholar
  176. Jakovlev, V., Thiemer, K., Habersang, S., Achterrath-Tuckermann, U., von Schlichtegroll, A., Sofia, R.D.: Über allgemeine pharmakologische Untersuchungen mit Tinofedrin. Arzneim. Forsch. 28, 1335–1343 (1978)Google Scholar
  177. Jansen, W.: Die zerebrale Leistungsschwäche im Blickpunkt therapeutischer Bemühungen doppelblinde Vergleichsprüfung mit encephabol forte und weiteren neurotropen Substanzen bei ambulanten geriatrischen Patienten. Therapiewoche 30, 1126, 1129–1131 (1980)Google Scholar
  178. Jobin, F.: Acetylsalicylic acid, hemostasis and human thromboembolism. Semin. Thromb. Hemostas. 4, 199–240 (1978)Google Scholar
  179. Jovanovic, U.J.: Polygraphische Registrierungen nach parenteraler Applikation von 3,7-dime-thyl-l(5-oxo-hexyl)-xanthin (BL 191). Arzneim. Forsch. 22, 994–999 (1972)Google Scholar
  180. Judge, T.G., Urquart, A., Blakemore, C.B.: Cyclandelate and mental function, a double blind crossover trial in normal elderly subjects. Age Ageing 2, 121–124 (1973)PubMedGoogle Scholar
  181. Kaindl, F.: Rheographie peripherer Arterien — eine neue Methode zur Beurteilung arterieller Gefäße. Arch. Kreisl.-Forsch. 20, 247–286 (1954)Google Scholar
  182. Kanig, K., Hoffmann, Kh.: Der 32P-Einbau in Adenosinphosphate des Rattengehirns nach zweiwöchiger oraler Verabreichung von Vincamin. Arzneim. Forsch. 29, 33–34 (1979)Google Scholar
  183. Kanig, K., Nitschki, J., Peiler-Ischikawa, K.: Der Einfluß von Naftdrofuryl auf den 32P-Ein-bau in Nukleinsäuren und Adenosinphosphate des Rattengehirns. Arzneim. Forsch. 29, 33–34 (1979)Google Scholar
  184. Karlsberg, P., Elliott, H.W., Adams, J.E.: Effect of various pharmacologic agents on cerebral arteries. Neurology (Minneap.) 13, 112–778 (1963)Google Scholar
  185. Karpati, E., Szporny, L.: General and cerebral haemodynamic activity of ethyl apovincaminate. Arzneim. Forsch. 26, 1908–1912 (1976)Google Scholar
  186. Kazda, S., Hoffmeister, F.: Effect of some cerebral vasodilators on the postischaemic impaired cerebral reperfusion in cats. Arch. Pharmacol. Suppl. 307, R43 (1979)Google Scholar
  187. Kazda, S., Towart, R.: Differences in the effects of the calcium antagonists nimodipine (BAY e 9736) and bencyclan on cerebral and peripheral vascular smooth muscle. Brit. J. Pharmacol. 72, 582–3 P (1981)Google Scholar
  188. Kazda, S., Hoffmeister, F., Garthoff, B., Towart, R.: Prevention of the postischemic impaired reperfusion of the brain by nimodipine (BAY e 9736). Acta Neurol. Scand. 60, 302–303 (1979)Google Scholar
  189. Kellner, H.: Zur Behandlung chronischer arterieller Durchblutungsstörungen. Doppelblindversuch mit Trendal 400. Münch. Med. Wochenschr. 118, 1399–1402 (1976)Google Scholar
  190. Kety, S.S.: Human cerebral blood flow and oxygen consumption as related to ageing. Res. Publ. Assoc. Nerv. Ment. Dis. 35, 31–45 (1956)Google Scholar
  191. Kiss, T., Szmolenszky, T., Lelkes, J., Tekeres, M.: Die Wirkung der Vasodilatatoren Bencyclan und Tolazolin auf die Muskeldurchblutung im pharmakologischen und klinischen Experiment. Therapiewoche 22, 2791–2792 (1972)Google Scholar
  192. Klausberger, E., Rajna, P.: Cerebrale Zirkulationsvorgänge unter der Einwirkung von Bencyclan. Arzneim. Forsch. 20, 1457–1460 (1970)Google Scholar
  193. Klein, K., Siedek, H.: Zur Erfassung intra- und extrazerebraler Kreislaufveränderungen mit neuen Methoden. Med. Welt 21, 1167–1171 (1965)PubMedGoogle Scholar
  194. Klein, K., Siedek, H.: Zum Verhalten des zerebralen Gefäßwiderstandes unter sympathikoly-tischem Einfluß. Wien. Med. Wochenschr. 116, 20–22 (1966)PubMedGoogle Scholar
  195. Kloeze, J.: Relationship between chemical structure and platelet-aggregation activity of prostaglandins. Biochim. Biophys. Acta 187, 285–292 (1969)PubMedGoogle Scholar
  196. Köhler, E., Motzer, S., Greeff, K.: Die kardiodepressive Wirkung des Bencyclans. Res. Exp. Med. 165, 111–125(1975)Google Scholar
  197. Kohlmeyer, K.: Der Einfluß eines neuen Vasodilatators (Bencyclan) auf die allgemeine und regionale Hirndurchblutung. Herz Kreisl. 4, 196–203 (1972)Google Scholar
  198. Koppenhagen, K., Wenig, H.G., Müller, K.: The effect of pentoxifylline (“Trental”) on cerebral blood flow: a double blind study. Curr. Med. Res. Opin. 4, 681–684 (1977)Google Scholar
  199. Kovacs, I.B., Csalay, L., Csakvary, G.: Antithrombotic and fibrinolytic effect of bencyclane. Arzneim. Forsch. 21, 1553–1556 (1971)Google Scholar
  200. Kraupp, O., Wolner, E., Adler-Kastner, L., Chirikdjian, J.J., Ploszczanski, B., Tuisl, E.: Die Wirkung von Hexobendin auf Sauerstoffverbrauch, Energetik und Substratstoffwechsel des Herzens. I Versuche mit intravenös verabreichten Einzeldosen. Arzneim. Forsch. 16, 692–696 (1966a)Google Scholar
  201. Kraupp, O., Wolner, L., Adler-Kastner, L., Chirikdjian, J.J., Ploszczanski, B., Tuisl, E.: Die Wirkung von Hexobendin auf Sauerstoffverbrauch, Energetik und Substratstoffwechsel des Herzens. IL Versuche mit intravenösen Infusionen: Arzneim. Forsch. 16, 697–705 (1966 b)Google Scholar
  202. Kraupp, O., Nell, G., Raberger, G., Stühlinger, W.: The effect of hexobendine on cerebral blood flow and metabolism. Arzneim. Forsch. 19, 1691–1698 (1969)Google Scholar
  203. Küchle, HJ.: Zur Therapie der akuten arteriellen Durchblutungsstörungen von Netzhaut und Sehnerv. Klin. Monatsbl. Augenheilkd. 171, 395–400 (1977)PubMedGoogle Scholar
  204. Kukovetz, W.R., Poech, G.: Inhibition of cyclic-3′,5′-nucleotide-phosphodiesterase as a possible mode of action of papaverine and similarly acting drugs. Arch. Pharmakol. 267, 189–194 (1970)Google Scholar
  205. Kukovetz, W.R., Pölch, G., Holzmann, S., Paietta, E.: Zum Wirkungsmechanismus von Bencyclan an der glatten Muskulatur. Arzneim. Forsch. 25, 722–726 (1975)Google Scholar
  206. Lavrentieva, N.B., Mchedlishvili, G.I., Plechkova, E.K.: Distribution and activity of Cholinesterase in nervous structures of the pial arteries (a histochemical study). Bull. Biol. Med. Exp. U.R.S.S. 64, 110–113 (1968)Google Scholar
  207. Lebedeva, N.V., Makarova, G.V.: Izmenenie parametra asimmetrii frontov voln EEG u bolnychs naruschenijami mozgovogo krovoobraschchenija pri lechenii istenonom: Z. Nevropatol. Psikhiatr. 75, 1619–1624 (1975)Google Scholar
  208. Lehrach, F., Müller, R.: Ergebnisse der klinischen Prüfung des Vaostherapeuticums 3,7-Dime-thyl-l-(5-oxo-hexyl)-xanthin (BL 191). Arzneim. Forsch. 21, 1171–1174 (1971)Google Scholar
  209. Levy, L.L., Wallace, J.D.: Cerebral blood flow regulation. II. Vasodilator mechanisms. Stroke 8, 189–193 (1977)PubMedGoogle Scholar
  210. Lievre, M., Ollagnier, M., Faucon, G.: Einfluß auf die zerebrale Durchblutung und α-sympa-tholytische Eigenschaften von Nicergolin. Arzneim. Forsch. 29, 1227–1231 (1979)Google Scholar
  211. Lim, C.C., Cook, P.J., James, I.M.: The effect of an acute infusion of vincamine and ethyl apovincaminate on cerebral blood flow in healthy volunteers. Br. J. Clin. Pharmacol. 9, 100–101 (1980)PubMedGoogle Scholar
  212. Linee, P., Lacroix, P., Le Polles, J.B., Aurousseau, M., Boulu, R., van den Driessche, J., Albert, O.: Cerebral metabolic, hemodynamic and antihypoxic properties of 1-eburnamonine. Eur. Neurol. 17, 113–120(1979)Google Scholar
  213. Malaisse, W.J.: Calcium-antagonists and islet function. X. Effect of suloctidil. Arch. Int. Pharmacodyn. 228, 339–344 (1977)Google Scholar
  214. Marolda, M., Fragassi, N., Buscaino, G.A.: Clinical evaluation of (-) Eburnamonine in comparison with nicergoline in patients suffering from chronic brain ischemia. Eur. Neurol. 17, 159–166 (1979)Google Scholar
  215. Masotti, G., Poggesi, L., Galanti, G., Neri Serneri, G.G.: Stimulation of prostacyclin by dipyridamole. Lancet 1979 I, 1412Google Scholar
  216. Matsuda, M., Meyer, J.S., Ott, E.O., Aoyagi, M., Tagashira, Y.: Cholinergic influence on auto-regulation and CO2 responsiveness of the brain. Circulation 50, III–90 (Abstr.) (1974)Google Scholar
  217. McElroy, F.A., Philp, R.B.: Relative potencies of dipyridamole and related agents as inhibitors of cyclic nucleotide phosphodiesterases: possible explanation of mechanism of inhibition of platelet function. Life Sci. 17, 1479–1494 (1975)PubMedGoogle Scholar
  218. McHenry, L.C.: Cerebral vasodilator therapy in stroke. Stroke 3, 686–691 (1972)PubMedGoogle Scholar
  219. McHenry, L.C., Jaffe, M.E., Kawamura, J., Goldberg, H.I.: Hydergine effect on cerebral circulation in cerebrovascular disease. J. Neurol. Sci. 13, 475–480 (1971)PubMedGoogle Scholar
  220. McHenry, L.C., Jaffe, M.E., West, J.W., Cooper, E.S., Kenton, E.J., Kawamura, J., Oshino, T., Goldberg, H.I.: Regional cerebral blood flow and cardiovascular effects of hexobendine in stroke patients. Neurology (Minneap.) 22, 217–223 (1972)Google Scholar
  221. Meer-Van Manen van der, A.H.E.: Klinische evaluatie van cinnarizine bij geriatrische patieenten. Ned.Tijdschr. Geneesk. 111, 256–261 (1967)Google Scholar
  222. Meng, K.: Tierexperimentelle Untersuchungen zur antithrombotischen Wirkung von Acetylsalicylsäure. Ther. Ber. 47, 69–79 (1975)Google Scholar
  223. Meng, K.: Tierexperimentelle Thrombose und Behandlung mit Acetylsalicylsäure. Med. Welt 27, 1359–1362 (1976)PubMedGoogle Scholar
  224. Meng, K., Seuter, F.: Effect of acetylsalicylic acid on experimentally induced arterial thrombosis in rats. Naunyn-Schmiedebergs Arch. Pharmacol. 301, 115–119 (1977)PubMedGoogle Scholar
  225. Merory, J., Du Bonlay, G.H., Marshall, J., Morris, J., Ross Russell, R.W., Symon, L., Thomas, D.J.: Effect of tinofedrin (Homburg D 8955) on cerebral blood flow in multi-infarct dementia. J. Neurol. Neurosurg. Psychiatry 41, 900–902 (1978)PubMedGoogle Scholar
  226. Meyer, J.S., Deshmuch, V.D., Welch, K.M.A.: Experimental studies concerned with the pathogenesis of cerebral ischaemia and infarction. In: Cerebral Arterial Disease. Ross Russell, R.W. (ed.), pp. 57–84. Edinbourgh, London: Churchill Livingstone 1976Google Scholar
  227. Meyer, J.S., Gotoh, F., Gilroy, J., Nara, N.: Improvement in brain oxygenation and clinical improvement in patients with stroke treated with papaverin hydrochlorid. J. Am. Med. Assoc. 194, 957–961 (1965)Google Scholar
  228. Meyer, J.S., Kanda, T., Shinohara, Y., Fukuuchi, Y., Shimazu, K., Ericsson, A.D., Gordon, W.H.: Effect of hexobendine on cerebral hemispheric blood flow and metabolism. Neurology (Minneap.) 21, 691–702 (1971)Google Scholar
  229. Meyer, J.S., Mathew, N.T., Hartmann, A.: Orally administered betahistine and regional cerebral blood flow in cerebrovascular disease. J. Clin. Pharmacol. 14, 280–289 (1974)PubMedGoogle Scholar
  230. Meyer, J.S., Welch, K.M.A.: Contribution of platelet aggregation and serotonin release to progressive cerebral infarction. In: Platelet aggregation in the pathogenesis of cerebrovascular disorders (Abstracts: Round Rable Conference, Rome, 1974). Fazio, C. (ed.), pp. 67–75 (1974)Google Scholar
  231. Meynaud, A., Grand, M., Fontaine, L.: Beeinflussung der Hirndurchblutung und des Hirnstoffwechsels durch Naftidrofuryl. Presented at International Symposium on CBF. Toulouse 1972Google Scholar
  232. Meynaud, A., Grand, M., Fontaine, L.: Effect of naftidrofuryl upon energy metabolism of the brain. Arzneim. Forsch. 23, 1431–1436 (1973)Google Scholar
  233. Mikus, P.: Klinische, physiologische und neurophysiologische Ergebnisse einer Doppelblindstudie mit Vincamin-Cromesilat bei Patienten mit cerebraler Durchblutungsinsuffizienz. Arzneim. Forsch. 28, 2165–2168 (1980)Google Scholar
  234. Mikus, P., Polak, O., Ochsenreither, A.M.: Klinische und elektroenzephalographische Ergebnisse eines Doppelblindversuches mit Vincamin (Pervincamin®) bei fortgeschrittener Zerebralsklerose. Pharmakopsychiatry 6, 39–49 (1973)Google Scholar
  235. Millikan, C.H., McDowell, F.H.: Treatment of transient ischemic attacks. Stroke 9, 299–308 (1978)PubMedGoogle Scholar
  236. Mills, D.C.B., Smith, J.B.: The influence on platelet aggregation of drugs that affect the accumulation of adenosine 3′,5′-cyclic monophosphate in platelets. Biochem. J. 121, 185–196 (1971)PubMedGoogle Scholar
  237. Miyazaki, M.: Effect of cerebral circulatory drugs on cerebral and peripheral circulation, with special reference to aminophylline, papaverine, cyclandelate, and isoxuprine. Jpn. Circulat. J. 35, 1053–1057 (1971)Google Scholar
  238. Molnar, G., Keller, L.: Die Wirkung von Bencyclan auf die Durchblutung der Extremitäten von Hunden nach intraarterieller Gabe. Arzneim. Forsch. 20, 1370–1371 (1970)Google Scholar
  239. Moncada, S., Korbut, R.: Dipyridamole and other phosphodiesterase inhibitors act as antithrombotic agents by potentiating endogenous prostacyclin. Lancet 1978 I, 1286–1289Google Scholar
  240. Moncada, S., Vane, J.R.: The discovery of prostacyclin — A fresh insight into arachidonic acid metabolism. In: Biochemical aspects of prostaglandins and thromboxanes. Kharash, N., Fried, J. (eds.), pp. 155–177. New York, San Francisco, London: Academic Press 1977Google Scholar
  241. Moneada, S., Vane, J.R.: Mode of action of aspirin-like drugs. Adv. Intern. Med. 24, 1–22 (1979)Google Scholar
  242. Moneada, S., Gryglewski, R.J., Bunting, S., Vane, J.R.: An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation. Nature 263, 663–665 (1976)Google Scholar
  243. Moneada, S., Flower, R.F., Russell-Smith, N.R.: Dipyridamole and platelet function. Lancet 1978 II, 1257–1258Google Scholar
  244. Moretti, A.: Metabolische und neurochemische Wirkung von Nicergolin auf das Zentralnervensystem: Übersicht über die experimentellen Untersuchungen. Arzneim. Forsch. 29, 1213–1223 (1979)Google Scholar
  245. Mucci, P., Sternieri, E.: Influenza della papaverina sulla irrorazione cerebrale del coniglio. Boll. Soc. Ital. Biol. Sper. 44, 965–969 (1968)PubMedGoogle Scholar
  246. Müller, R.: Zum gegenwärtigen Stand der Hämorheologie aus klinisch-pharmakologischer Sicht. Therapiewoche 30, 2440–2451 (1980)Google Scholar
  247. Mustard, J.F., Packham, M.A.: Platelets, thrombosis, and drugs. Drugs 9, 19–76 (1975)PubMedGoogle Scholar
  248. Mustard, J.F., Murphy, E.A., Robinson, G.A., Roswell, H.C., Ozge, A., Crookston, J.H.: Blood platelet survival. Thromb. Diath. Haemorrh. 13, 245–275 (1964)Google Scholar
  249. Nayler, W.G., Ferrari, R., Williams, A.: Protective effect of pretreatment with verapramil, nifedipine, and propranolol on mitochondrial function in the ischaemic and reperfused myocardium. Am. J. Cardiol. 46, 242–248 (1980)PubMedGoogle Scholar
  250. Neri Seneri, G.G., Gensini, G.F., Abbate, R., Favilla, S., Laureano, R.: Modulation by dipyridamole of the arachidonic acid metabolic pathway in platelets. An in vivo and in vitro study. Thromb. Haemostas. 42, 197 (1979)Google Scholar
  251. Nishino, H.: Effects of vasodilators on tissue blood flow. Folia Pharmacol. Jpn. 70, 621–628 (1974)Google Scholar
  252. N.N.: Pyridimolcarbamat. Wien. Klin. Wochenschr. 84, 200–201 (1972)Google Scholar
  253. Norre, M.: Suloctidil in vertigo: een dubbel-blind studie tegenover placebo. Ars. Medici 6, 1383–1391 (1977)Google Scholar
  254. Obermeier, K., Thiemer, K., Schlichtegroll, V.A.: Einfluß von Tinofedrin auf den zerebralen Energiestoffwechsel von normotonen, hypotonen und hypoämischen Ratten nach Carotis-Verschluß. Arzneim. Forsch. 28, 1354–1360 (1978)Google Scholar
  255. O’Brien, J.R.: Effect of antiinflammatory agents on platelets. Lancet 1968 I, 894–895Google Scholar
  256. O’Brien, M.D., Veall, N.: Effects of cyclandelate on cerebral cortex perfusion-rates in cerebrovascular disease. Lancet 1966 II, 729–730Google Scholar
  257. Olesen, J.: Cerebral blood flow. Methods for measurement. Regulation, effects of drugs and changes in disease. Acta Neurol. Scand. 50, 1–34 (1974)Google Scholar
  258. Olesen, J., Paulson, O.B.: The effect of intra-arterial papaverine on the regional cerebral blood flow in patients with stroke or intracranial tumor. Stroke 2, 148–149 (1971)PubMedGoogle Scholar
  259. Olesen, J., Skinhoj, E.: Effects of ergot alkaloids (hydergine) on cerebral haemodynamics. Acta Pharmacol. Toxicol. 31, 75–85 (1972)Google Scholar
  260. Ott, E., Lechner, H.: The influence of nimodipine on cerebral blood flow in patients with subacute cerebral infarction. In: Pathophysiology and pharmacotherapy of cerebrovascular doisorders. Betz, E. (ed.). in press 1981Google Scholar
  261. Packham, M.A., Jenkins, C.S.P., Kinlough-Rathbone, R.L., Mustard, J.F.: Agents influencing platelet adhesion to surfaces and the release reaction. Circulation 44, 67 Suppl. 2 (Abstr.) (1971)Google Scholar
  262. Pathy, J., Menon, G., Reynolds, A., Van Strik, R.: Betahistine hydrochloride (serc) in cerebrovascular disease: A placebo-controlled study. Age Ageing 6, 179–184 (1977)PubMedGoogle Scholar
  263. Paulson, O.: Mechanism of action of aminophylline and of hypocapnia on cerebrovascular disease. Acta Neurol. Scand. 46, 251 (1970)PubMedGoogle Scholar
  264. Pech, A., Gitenet, P.: La pervincamine en O.-R.-L. Ann. Otol-Laryngol. 89, 469–474 (1972)Google Scholar
  265. Pedersen, A.K.: Dipyridamole and platelet aggregation. Lancet 1978 II, 270Google Scholar
  266. Perkin, G.D.: Anticoagulants in transient ischaemic attacks. In: Progress in Stroke. Greenhalgh, R.M., Rose, F.C. (eds.), pp. 181–203. Kent: Pitman Medical 1979Google Scholar
  267. Persantine-Aspirin Reinfarction Study Research Group: Persantine and Aspirin in coronary heart disease. Circulation 62, 449–461 (1980)Google Scholar
  268. Philp, R.B., Francey, I., McElroy, F.: Effects of dipyridamole and five related agents on human platelet aggregation and adenosine uptake. Thrombos. Res. 3, 35–50 (1973)Google Scholar
  269. Ponari, O., Civardi, E., Dettori, A.G., Megha, A., Poti, R., Bulletti, G.: In vitro effects of ben-cyclan on coagulation, fibrinolysis, and platelet function. Arzneim. Forsch. 26, 1532–1538 (1976)Google Scholar
  270. Pourrias, B., Raynaud, G., Courbevoie, Fr.: Action de quelques agents vaso-actifs sur l’irrigation sous corticale du lapin et du chien. Thérapie 27, 849–860 (1972)PubMedGoogle Scholar
  271. Prencipe, M., Pisarri, F.M., Cecconi, V., Agnoli, À.: Platelet aggregation in cerebrovascular patients. In: Platelet aggregation in the pathogenesis of cerebrovascular disorders (Abstracts: Round Table Conference, Rome 1974). Fazio, C. (ed.), pp. 49–53Google Scholar
  272. Puig-Parellada, J., Planas, J.M.: Action of selective inhibitor of thromboxane synthetase on experimental thrombosis induced by arachidonic acid in rabbit. Lancet 1977 I, 40Google Scholar
  273. Purves, M.J.: The physiology of the cerebral circulation. Cambridge: Cambridge University Press 1972Google Scholar
  274. Quadbeck, H., Lehmann, E.: Die Veränderung des oxidativen Glukosestoffwechsels des Gehirns unter langfristiger Xantinol-nicotinat-Medikation. Arzneim. Forsch. 28, 1531–1532 (1978)Google Scholar
  275. Raaflaub, J.: Zur Umwandlung von ß-Pyridylcarbinol in Nikotinsäure im tierischen Organismus. Experientia 22, 258–259 (1966)PubMedGoogle Scholar
  276. Regli, F., Yamaguchi, T., Waltz, A.G.: Cerebral circulation. Effects of vasodilating drugs on blood flow and the microvasculature of ischemic and nonischemic cerebral cortex. Arch. Neurol. 24, 467–474 (1971)PubMedGoogle Scholar
  277. Regli, F., Yamaguchi, T., Waltz, A.: Cerebral circulation, effects of vasodilating drugs on blood flow and the microvasculature of ischemic and non-ischemic cerebral cortex. Arch. Neurol. 24, 476–484 (1972)Google Scholar
  278. Reichertz, P.L., Kruskemper, G., Fröhlich, W.D., Stadeler, J., Konrad, D., Schaar, W., Overall, J.E., Dickhöfer, C.: Untersuchungen des physischen und psychischen Verhaltens und deren medikamentöse Beeinflußbarkeit bei Altersheiminsassen. Sonderdruck aus „Verhandlungen der Deutschen Gesellschaft für innere Medizin“, 73. Kongreß. München: J.F. Bergmann 1967Google Scholar
  279. Reimann-Hunziker, R., Reimann-Hunziker, G.J.: Wirkung von Cinnarizin bei Arteriosclerosis cerebri. Besserung der Symptome durch vermehrte Sauerstoffzufuhr und -ausnützung mittels Cinnarizin. Praxis 39, 1239–1242 (1969)Google Scholar
  280. Rieger, H., Klose, H.J., Schmid-Schönbein, H., Wurzinger, L.: The effects of orally administered bencyclane on spontaneous platelet aggregation (PA) as a function of bencyclane concentration in coded samples. Thrombos. Res. 12, 353–356 (1978)Google Scholar
  281. Rifkin, P.L., Zucker, M.B.: The effect of dipyridamol and RA 233 on human platelet function in vitro. Thrombos. Diathes. Haemorrh. 29, 694–700 (1973)Google Scholar
  282. Ritter, R.M., Nail, H.R., Tatum, P., Blazi, M.: The effect of papaverine on patients with cerebral arteriosclerosis. Clin. Med. 78, 18–22 (1971)Google Scholar
  283. Roba, J., Reuse Blom, S., Lambelin, G.: In vivo antispasmodic activity of suloctidil. Arch. Int. Pharmacodyn. 221, 54–59 (1976 a)PubMedGoogle Scholar
  284. Roba, J., Claeys, M., Lambelin, G.: Antiplatelet and antithrombogenic effect of suloctidil. Eur. J. Pharmacol. 37, 265–274 (1976b)PubMedGoogle Scholar
  285. Roba, J., Bourgain, R., Andries, R., Claeys, M., Van Opstal, W., Lambelin, G.: Antagonism by suloctidil of arterial thrombus formation in rats. Thrombos. Res. 9, 585–594 (1976c)Google Scholar
  286. Rodvien, R., Mielke, C.H.: Platelet and antiplatelet agents in strokes. Stroke 9, 403–405 (1978)PubMedGoogle Scholar
  287. Rokitansky, C.: Von: Handbuch der pathologischen Anatomie, vol.4. (1842)Google Scholar
  288. Rosenberg, F.J., Gimber-Phillips, P.E., Groblewski, G.E., Davison, C., Phillips, D.K., Goral-nick, S.J., Canhill, E.D.: Acetylsalicyclic acid: Inhibition of platelet aggregation in the rabbit. J. Pharmacol. Exp. Ther. 179, 410–418 (1971)PubMedGoogle Scholar
  289. Rosenberger, L., Triggle, D.J.: Calcium, calcium translocation, and specific calcium antagonists. In: Calcium in drug action. Weiss, G.B. (ed.), pp. 3–31. New York: Plenum Press 1978Google Scholar
  290. Rosenblum, W.J., El-Sabban, F.: Platelet aggregation in the cerebral microcirculation. Circ. Res. 40, 320–328 (1977)PubMedGoogle Scholar
  291. Rothlin, E., Taeschler, M.: Zur Wirkung von Adrenalin und Hydergin auf die Hirndurchblutung. Helv. Physiol. Pharmacol. Acta 9, 37–39 (1951)Google Scholar
  292. Rozenberg, M.C., Walker, C.M.: The effect of pyrimidine compounds on the potentiation of adenosine inhibition of aggregation, on adenosine phosphorylation and phosphodiesterase activity of blood platelets. Br. J. Haematol. 24, 409–418 (1973)PubMedGoogle Scholar
  293. Sacle, P., Battock, D., Genton, E.: Effects of Clofibrate and sulfinpyrazone on platelet survival in coronary artery disease. Circulation 52, 473–476 (1975)Google Scholar
  294. Sakamoto, N., Terai, M., Takenaka, T., Maeno, H.: Inhibition of cyclic AMP phosphodiesterase by 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylic acid 3–2-(N-benzyl-N-methylamino) ethyl ester 5-methyl ester hydrochloride (YC-93), a potent vasodilator. Biochem. Pharmacol. 27, 1269–1274 (1977)Google Scholar
  295. Saletu, B., Anderer, P.: Zur Vigilanzförderung bei geriatrischen Patienten durch Tinofedrin i.v./Doppelblinde, Plazebo-kontrollierte quantitative Pharmako-EEG-Untersuchungen. Arzneim. Forsch. 30, 1218 (1980a)Google Scholar
  296. Saletu, B., Anderer, P.: Double-blind placebo-controlled quantitative pharmaco-EEG investigations after tinofedrine i.v. in geriatric patients. Curr. Ther. Res. 28, 1–15 (1980 b)Google Scholar
  297. Samuelsson, B., Folco, G., Granström, E., Kindahl, H., Malmsten, C.: Prostaglandins and thromboses: Biochemical and physiological considerations. In: Advances in Prostaglandin and Thromboxane Research. Coceanin, F., Olley, P.M. (eds.), vol.4, pp. 1–25. New York: Raven Press 1978Google Scholar
  298. Sandok, B.A., Furlan, A.J., Whisnant, P., Sundt, I.M., jr.: Guidelines for the management of transient ischemic attacks. Maro Clin. Proc. 53, 665–674 (1978)Google Scholar
  299. Saratikov, A.S., Usov, L.A., Filimonova, L.T., Gorshkova, V.K., Dimitrienko, V.F.: Galidore action on the hemodynamics and oxidative metabolism of the brain. Farmakol. Toksikol. 34, 668–671 (1971)PubMedGoogle Scholar
  300. Schindler, M.: Über die Wirkung von Papaverin, Hydergin, BAY e 9736 und Nifedipin auf die Aktivität der zytoplasmatischen („High-KM“-) und membrangebundenen („Low KM“-) cAMP-Phosphodiesterasen des Rattengehirns und -herzens. Inaugural-Dissertation zur Erlangung des Doktorgrades der Medizin der Fakultät für theoretische Medizin am Universitätsklinikum der Gesamthochschule Essen, 1979Google Scholar
  301. Schüttler, M., Furienmeier, A.: Vincamine, ein Alkaloid aus Vinca minor L. (Apocyanaceae). Helv. Chim. Acta 36, 2017–2020 (1953)Google Scholar
  302. Schmid-Schönbein, H.: Rheological properties of the blood under normal and pathological conditions. In: Brain and heart infarct. Zülch, K.J., Kaufmann, W., Hossmann, K.-A., Hossmann, V. (eds.), pp. 96–106. Berlin, Heidelberg, New York: Springer 1977Google Scholar
  303. Schmid-Schönbein, H.: Der gegenwärtige Stand der Hämorheologie — Methoden, Befunde und Bedeutung für die Physiologie und Pathologie des Blutkreislaufs. Wien. Klin. Wochenschr. 90, 245–253 (1978)PubMedGoogle Scholar
  304. Schmidt, R.: Eine neue Methode zur Erzeugung von Thromben durch Unterkühlung der Gefäßwand und ihre Anwendung zur Prüfung von Acetylsalicylsäure und Heparin. Inaugural-Dissertation, Gießen, 1975Google Scholar
  305. Schneider, E., Fischer, P.A., Jacobi, P.: Bencyclan (Fludilat) in der Behandlung lokaler Hirndurchblutungsstörungen. Med. Klin. 71, 1611–1616 (1977)Google Scholar
  306. Schneider, M., Wiemers, K.: Über die Wirkung der hydrierten Mutterkornalkaloide auf die Gehirndurchblutung. Klin. Wochenschr. 29, 580–581 (1951)PubMedGoogle Scholar
  307. Seidel, G., Endell, W.: Effect of xanthinol nicotinate treatment on platelet aggregation. Int. J. Clin. Pharmacol. 15, 139–143 (1977)Google Scholar
  308. Sen, S., Chakravarty, A.: Clinical experience with pentoxifylline in occlusive cerebrovascular disorders. Angiology 28, 340–344 (1977)PubMedGoogle Scholar
  309. Seuter, F.: Inhibition of platelet aggregation by acetylsalicylic acid and other inhibitors. Hae-mostasis 5, 85–95 (1976)Google Scholar
  310. Seuter, F., Busse, W.D.: Arachidonic acid induced mortality in animals — An appropriate model for the evaluation of antithrombotic drugs? In: Arachidonic acid metabolism in inflammation and thrombosis. Agents and actions. Brune, K., Baggiolini, E. (eds.), Suppl. 4, pp. 175–183. Basel, Boston, Stuttgart: Birkhäuser 1979Google Scholar
  311. Seuter, F., Sitt, R., Busse, W.-D.: Experimentally induced thromboatherosclerosis in rats and rabbits. Folia Angiologica 28, 85–87 (1980)Google Scholar
  312. Shimamoto, T., Takashima, Y., Kobayashi, M., Moriya, K., Takabashi, T.: A thromboxane A2-antagonistic effect of pyridinolcarbamate and phthalazinol. Proc. Jpn. Acad. 52, 591 (1976)Google Scholar
  313. Shimamoto, T., Kobayashi, M., Takahashi, T., Takashima, Y., Motomiya, T., Morooka, S., Numano, F.: The production of heart attacks and cerebral stroke by thromboxane A2 mixtures and their prevention with EG 626 (phthalazinol). Thromb. Haemostas. 38, 132 (1977)Google Scholar
  314. Silver, M.J., Hoch, W., Kocsis, J.J., Ingerman, C.M., Smith, J.B.: Arachidonic acid causes sudden death in rabbits. Science 183, 1085–1087 (1974)PubMedGoogle Scholar
  315. Sixma, J.J., Trieschnigg, A.M.C., De Graaf, S., Bouma, B.N.: In vivo inhibition of human platelet function by VK 744. Scand. J. Haemat. 9, 226–230 (1972)PubMedGoogle Scholar
  316. Skinhoj, E., Paulson, O.B.: The mechanism of action of aminophylline upon cerebral vascular disorders. Acta Neurol. Scand. 46, 129–140 (1970)PubMedGoogle Scholar
  317. Smith, W.L., Philippus, M.J., Lowrey, J.B.: A comparison of psychological and psychophysical test patterns before and after receiving papaverine HCl. Cur. Therap. Res. 10, 428–431 (1968)Google Scholar
  318. Sokoloff, L.: The action of drugs on the cerebral circulation. Pharmacol. Rev. 11, 1–85 (1959)PubMedGoogle Scholar
  319. Sokoloff, L.: Effects of normal ageing on cerebral circulation and energy metabolism. In: Brain function in old age. Hoffmeister, F., Müller, C. (eds.), pp. 368–384. Berlin, Heidelberg, New York: Springer 1979Google Scholar
  320. Solti, F.: Die Wirkung von Bencyclan auf die Blutdurchströmung der Extremitäten. Arzneim. Forsch. 20, 1358–1360 (1970)Google Scholar
  321. Solti, F., Krasznai, F., Iskum, M., Gyertyanfi, G.: Die Neuverteilung des Herzminutenvolumens auf einzelne Organe unter der Wirkung von Bencyclan. Arzneim. Forsch. 20, 1360–1361 (1970)Google Scholar
  322. Spaet, T.H., Gaynor, E., Stermerman, M.B.: Thrombosis, atherosclerosis, and endothelium. Am Heart J. 87, 661–668 (1974)PubMedGoogle Scholar
  323. Spagnoli, A., Tognoni, G.: Ergot-alcaloids in clinical pharmacology and drug epidemiology. In: Tognoni, G., Garattini, S. (eds.), pp. 223–243. North Holland: Elsevier 1979Google Scholar
  324. Spehr, W.: Zur Zeitgestalt des Elektroencephalogramms unter Tinofedrin. Arzneim. Forsch. 28, 1312–1313 (1978)Google Scholar
  325. Spruill, J.H., Toole, J.F., Kitto, W., Miller, H.E.: A comparison of betahistine hydrochloride with placebo for vertebral-basilar insufficiency: A double-blind study. Stroke 6, 116–120 (1975)PubMedGoogle Scholar
  326. Steger, W.: Die Beeinflussung des Plättchenagglutinationstestes durch Xantinol-nicotinat. Med. Welt 24, 301–302 (1973)PubMedGoogle Scholar
  327. Steinhauer, H.B., Anhut, H., Hertting, G.: Inhibition of thromboxane-synthesis in mouse brain in vivo. Arch. Pharmacol. Suppl. 311, R 30–117 (1980)Google Scholar
  328. Streivhenberger, G., Boismare, F., Lauressergues, H., Lechat, P.: Modification par certains medicaments doués d’action vasculaire, des effets d’une anoxie ischémique encéphalique chez le chat. Thérapie 25, 1004–1016 (1970)Google Scholar
  329. Stroman, F., Thiemer, K.: Untersuchungen zur allgemeinen Herz- und Kreislaufwirkung des Tinofedrin. In press 1981Google Scholar
  330. Subbarao, K., Rucinsky, B., Rausch, M.A.: Binding of dipyridamole to human platelets and to alpha 1 acid glycoprotein and its significance for the inhibition of adenosine uptake. J. Clin. Invest. 60, 936–943 (1977)PubMedGoogle Scholar
  331. Suga, F., Snow, J.B.: Cochlear blood flow in response to vasodilating drugs and some related agents. Laryngoscope 79, 1956–1979 (1969)PubMedGoogle Scholar
  332. Szarvasi, E., Bayssat, M., Fontaine, L.: Dialcoylamino-esters et -éthéroxydes à activité antispasmodique. Compt. Rend. 260, 3095–3098 (1965)Google Scholar
  333. Szekeres, L.: Die hämodynamische Wirkung von Bencyclan. Arzneim. Forsch. 20, 1362–1367 (1970)Google Scholar
  334. Szewczykowski, J., Meyer, J.S., Kondo, A., Nomura, F., Teraura, T.: Effects of ergot alkaloids (hydergine) on cerebral hemodynamics and oxygen consumption in monkeys. J. Neurol. Sci. 10, 25–31 (1970)PubMedGoogle Scholar
  335. Szporny, L.: Pharmacologie de la vincamine et de ses dérivés. Actual. Pharmacol. 29, 87–117 (1976)Google Scholar
  336. Szporny, L., Görög, P.: The effect of vincamine on the blood pressure of the rat. Arch. Int. Pharmacodyn. 138, 451–461 (1962)PubMedGoogle Scholar
  337. Taeschler, M., Cerletti, A., Rothlin, E.: Zur Frage der Hyderginwirkung auf die Gehirnzirkulation. Helv. Physiol. Pharmacol. Acta 10, 120–137 (1952)PubMedGoogle Scholar
  338. Takenaka, T., Handa, J.: Cerebrovascular effects of YC-93, a new vasodilator, in dogs, monkeys and human patients. Int. J. Clin. Pharmacol. Biopharm. 17, 1–11 (1979)PubMedGoogle Scholar
  339. Teasdale, G.: Cerebrovascular effects of nimodipine. 2nd Beaune Conference. 1980Google Scholar
  340. Ten Cate, J.W., Gerritsen, J., van Geet-Weijers, J.: In vitro and in vivo experiences with VK 774. A new platelet function inhibitor. Path. Biol. 20, 76–81 (1972)Google Scholar
  341. Ten Cate, J.W., Vos, J., Oosterhuis, H., Prenger, D., Jenkins, C.S.P.: Spontaneous platelet aggregation in cerebrovascular disease. Thromb. Haemostas. 39, 223–229 (1978)Google Scholar
  342. Tesseris, J., Roggen, G., Caracalos, A., Triandafillou, D.: Effects of vincamin on cerebral metabolism. Eur. Neurol. 13, 195–202 (1975)PubMedGoogle Scholar
  343. Thiemer, K., Stroman, F., Szelenyi, I., Schlichtegroll v., A.: Pharmakologische Wirkung von Tinofedrin auf die zerebrale und periphere Hämodynamik des Hundes. Arzneim. Forsch. 28, 1343–1354 (1978)Google Scholar
  344. Thiery, E., Verwerft, E., van der Eecken, H.: Étude comparative en double aveugle avec permutation croisée suloctidil/placébo d’une population agée, présentant une détérioration mentale étiologie cérébro-vasculaire. Ars. Medici 32, 73–81 (1977)Google Scholar
  345. Thomas, D.J.: The influence of blood viscosity on cerebral blood flow and symptoms. In: Progress in stroke. Greenhalgh, R.M., Rose, F.C. (eds.), pp. 47–55. Kent: Pitman Medical 1979Google Scholar
  346. Toledo, J.B., Pisa, H., Marchese, M.: Clinical evaluation of cinnarizine in patients with cerebral circulatory deficiency. Arzneim. Forsch. 22, 448–451 (1972)Google Scholar
  347. Towart, R.: New pharmacological aspects of calcium antagonists. In: New aspects of unstable angina pectoris. Lichtlen, P.R., Balcon, R. (eds.). In press 1981Google Scholar
  348. Towart, R., Kazda, S.: The cellular mechanism of action of nimodipine (BAY e 9736), a new calcium antagonist. Br. J. Pharmacol. 67, 409 (1979)Google Scholar
  349. Towart, R., Kazda, S.: Selective inhibition of serotonin-induced contractions of rabbit basilar artery by nimodipine (BAY e 9736) IRCS. Med. Sci. Nervous Syst. 8, 206 (1980)Google Scholar
  350. Toyoda, M., Takagi, S., Seki, T., Takeoka, T., Gotoh, F.: Effect of a new vasodilator (Flunarizine) on the cerebral circulation. J. Neurol. Sci. 25, 371–375 (1975)PubMedGoogle Scholar
  351. Triner, L., Vulliemoz, Y., Schwartz, I., Nahas, G.G.: Cyclic phosphodiesterase activity and the action of papaverine. Biochem. Biophys. Res. Commun. 40, 64–69 (1970)PubMedGoogle Scholar
  352. Ts’ao, Ch., Ali, N., Kolb, T.: “Spontaneous” platelet aggregation: Its characteristics and relation to aggregation by other agents. Thromb. Haemostas. 39, 379–385 (1978)Google Scholar
  353. Tsu, E.C.: Antiplatelet drugs in arterial thrombosis: A review. Am. J. Hosp. Pharm. 35, 1507–1515 (1978)PubMedGoogle Scholar
  354. Vamosi, B., Moln’ar, L., Demeter, J., T’ury, F.: Comparative study of the effect of ethyl apovincaminate and xantinol nicotinate in cerebrovascular diseases. Immediate drug effects on the concentrations of carbohydrate metabolites and electrolytes in blood and CSF. Arzneim. Forsch. 26, 1980–1984 (1977)Google Scholar
  355. Van Breemen, C., Siegel, B.: The mechanism of action of α-adrenergic activation of the dog coronary artery. Circulat. Res. 46, 426–429 (1980)PubMedGoogle Scholar
  356. Van den Driessche, J., Lacroix, P., Linee, Ph., Le Polies, J.B., Pape, D., Allain, H.: Activity of some drugs on the electroencephalogram of curarized rats during acute and iterative hypercapnic anoxia hypotheses on mechanisms of action. Arch. Int. Pharmacodyn. 239, 62–77 (1979)Google Scholar
  357. Vane, J.R.: Inhibitors of prostaglandin, prostacyclin, and thromboxane synthesis. In: Advances in Prostagoandin and Thromboxane research. Coceani, F., Olley, P.M. (eds.), vol.4, pp. 27–43. New York: Raven Press 1978Google Scholar
  358. Van Nueten, Janssen, P.A.J.: Comparative study of the effects of flunarizine and cinnarizine on smooth muscles and cardiac tissues. Arch. Int. Pharmacodyn. 204, 37–55 (1973)PubMedGoogle Scholar
  359. Van Nueten, J.M., Vanhoutte, P.M.: Improvement of tissue perfusion with inhibitors of calcium ion influx. Biochem. Pharmacol. 29, 479–481 (1980)PubMedGoogle Scholar
  360. Van Schepdael, J.: Étude clinique de l’action du suloctidil sur la maladie cérébro-vasculaire chronique de la personne agée. Ars. Médici 32, 1506–1518 (1977)Google Scholar
  361. Vater, W., Kroneberg, G., Hoffmeister, F., Kaller, H., Meng, K., Oberdorf, A., Puls, W., Schloßmann, K., Stoepel, K.: Zur Pharmakologie von 4-(2′-Nitrophenyl)-2,6-dimethyl-1,4-dihydropyridin-3,5-dicarbonsäuredimethylester (Nifedipine), BAY a 1040. Arzneim. Forsch. 22, 1–170 (1972)Google Scholar
  362. Villa, R.F., Strada, P., Marzatico, F., Dagani, F.: Effect of (-) eburnamonine, papaverine, and UDP-glucose on cerebral energy state during and after experimental hypoxia and ischaemia in beagle dogs. Eur. Neurol. 17, 97–112 (1979)Google Scholar
  363. Wackenheim, A.: Le traitement de l’insuffisance vertébrobasilaire par le torental. Med. Act. 3, 6–8 (1976)Google Scholar
  364. Walter, L.A., Hunt, W.H., Fosbinder, R.J.: Beta-(2- and 4-pyridyalkyl)-amines. J. Am. Chem. Soc. 63, 2771–2773 (1941)Google Scholar
  365. Warembourg, H., Pruvot, P., Sueur, A., Lekieffre, J.: An experimental study of a vasodilator drug, CAA 40. Its effect on the vascularization of the brain, on the arterial blood pressure and on the electro-encephalogram. Thérapie 16, 125–129 (1961)Google Scholar
  366. Wechsler, R.I., Kleiss, I.M., Kety, S.S.: The effects of intravenously administered aminophyllin on cerebral circulation and metabolism in man. J. Clin. Invest. 29, 28–80 (1950)PubMedGoogle Scholar
  367. Weigelin, E., Sayegh, F.: Zur Objektivierung des cerebralen durchblutungsfördernden Effektes vasoaktiver Substanzen unter besonderer Berücksichtigung von Cinnarizin. In: Aktuelle Probleme der psychiatrischen Pharmakotherapie in Klinik und Praxis. Heinrich, K. (ed.), pp. 20–26. Stuttgart, New York: Schattauer 1969Google Scholar
  368. Weily, H.S., Genton, E.: Altered platelet function in patients with prosthetic mitral valves: Effects of sulfinpyrazone therapy. Circulation 42, 967–972 (1970)PubMedGoogle Scholar
  369. Weily, H.S., Steele, P.P., Davies, H., Pappas, G., Genton, E.: Platelet survival in patients in substitute heart valves. New Engl. J. Med. 290, 534–539 (1974)PubMedGoogle Scholar
  370. Weiss, H.J.: Antiplatelet drugs — A new pharmacologic approach to the prevention of thrombosis. Am. Heart J. 92, 86–102 (1976)PubMedGoogle Scholar
  371. Weiss, H.J., Aledort, L.M., Kochwa, S.: The effect of salicylates on the hemostatic properties of platelets in man. J. Clin. Invest. 47, 2169–2180 (1968)PubMedGoogle Scholar
  372. Wernitz, W.: Die Wirkung von Monotrean und seinen Komponenten auf die Hirndurchblutung. Vorläufige Mitteilung über die Untersuchungen mit Radiojod. Med. Welt 33, 1799–1801 (1969)PubMedGoogle Scholar
  373. Westreich, G., Alter, M., Lundgren, S.: Effect of cyclandelate on dementia. Stroke 6, 535–538 (1975)PubMedGoogle Scholar
  374. Whittier, J.R., Dhrymiotis, A.D.: Prevention of slow wave response to hyperventilation in the human electroencephalogram by a vasodilator. Angiology 13, 324–327 (1962)PubMedGoogle Scholar
  375. Wilcke, O.: Ergebnisse der Behandlung zerebraler Durchblutungsstörungen mit Cinnarizin. Med. Welt 27, 1472–1477 (1966)PubMedGoogle Scholar
  376. Willis, A.L.: An enzymatic mechanism for the antithrombotic and antihemostatic actions of aspirin. Science 183, 325–327 (1974)PubMedGoogle Scholar
  377. Witzmann, H.K., Blechacz, W.: Zustellung von Vincamin in der Therapie cerebrovasculärer Krankheiten und cerebraler Leistungsverminderung. Arzneim. Forsch. 27, 1238–1247 (1977)Google Scholar
  378. Wolfe, L.S.: Some facts and thoughts on the biosynthesis of prostaglandins and thromboxanes in brain. In: Advances in prostaglandin and thromboxane research. Coceani, F., Olley, P.M. (eds.), vol.4, pp.215–220. New York: Raven Press 1978Google Scholar
  379. Wu, K.K., Hoak, J.C.: Increased platelet aggregates in patients with transient ischemic attacks. Stroke 6, 521–524 (1975)PubMedGoogle Scholar
  380. Yarullin, K.K., Khadzhiev, D., Penyazeva, G.A., Levchenko, N.I.: The influence of stutgeron on the cerebral hemodynamics in patients with disorders of the cerebral circulation. Klin. Med. 50, 62–69 (1972)Google Scholar
  381. Yatsu, F.M.: Stroke therapy: Status of anti-platelet aggregation drugs (editorial). Neurology 27, 503–504 (1977)PubMedGoogle Scholar
  382. Zervas, N.T., Lavyne, M.H., Negoro, M.: Neurotransmitters and the normal and ischaemic cerebral circulation. New Engl. J. Med. 293, 812–816 (1975)PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1981

Authors and Affiliations

  • F. Hoffmeister
  • S. Kazda
  • F. Seuter

There are no affiliations available

Personalised recommendations